Detalhe da pesquisa
1.
In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Future Oncol
; 20(3): 131-143, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37807952
2.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259589
3.
Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.
BMC Cancer
; 21(1): 730, 2021 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34172037
4.
pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Mol Pharm
; 18(1): 87-100, 2021 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33231464
5.
A Primer on Chimera Associated Receptor T-Cells.
Mo Med
; 118(5): 460-465, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34658441
6.
The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.
J Biol Chem
; 293(12): 4334-4349, 2018 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29414775
7.
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.
Haematologica
; 103(1): 101-106, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29097499
8.
Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway.
BMC Cancer
; 18(1): 99, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29370782
9.
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 17(4): 496-508, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26968357
10.
A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.
Br J Haematol
; 169(1): 36-43, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25572917
11.
miR-21 mediates hematopoietic suppression in MDS by activating TGF-ß signaling.
Blood
; 121(15): 2875-81, 2013 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23390194
12.
Retinoic acid signaling pathways in development and diseases.
Bioorg Med Chem
; 22(2): 673-83, 2014 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24393720
13.
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Blood Cancer J
; 13(1): 147, 2023 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726298
14.
Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.
Clin Cancer Res
; 29(1): 60-66, 2023 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36255372
15.
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
J Clin Oncol
; 41(15): 2815-2826, 2023 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36888930
16.
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
J Clin Oncol
; 41(31): 4893-4904, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37703506
17.
Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced signaling protein-2 (WISP-2) regulates microRNA-10b via hypoxia-inducible factor-1α-TWIST signaling networks in human breast cancer cells.
J Biol Chem
; 286(50): 43475-85, 2011 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-22020939
18.
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.
J Biol Chem
; 286(28): 25211-23, 2011 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21532034
19.
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Blood Adv
; 6(17): 5132-5145, 2022 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35728048
20.
Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019.
Leuk Lymphoma
; 62(6): 1386-1395, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33416412